Innovent Biologics, Inc.
Innovent Biologics, Inc. Fundamental Analysis
Innovent Biologics, Inc. (1801.HK) shows weak financial fundamentals with a PE ratio of 88.95, profit margin of 6.30%, and ROE of 4.82%. The company generates $24.5B in annual revenue with strong year-over-year growth of 51.82%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 60.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 1801.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1801.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate1801.HK shows balanced valuation metrics.
Growth Score
Excellent1801.HK delivers strong and consistent growth momentum.
Financial Health Score
Excellent1801.HK maintains a strong and stable balance sheet.
Profitability Score
Weak1801.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1801.HK Expensive or Cheap?
P/E Ratio
1801.HK trades at 88.95 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 1801.HK's PEG of -3.50 indicates potential undervaluation.
Price to Book
The market values Innovent Biologics, Inc. at 3.74 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 94.29 times EBITDA. This signals the market has high growth expectations.
How Well Does 1801.HK Make Money?
Net Profit Margin
For every $100 in sales, Innovent Biologics, Inc. keeps $6.30 as profit after all expenses.
Operating Margin
Core operations generate 11.28 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.82 in profit for every $100 of shareholder equity.
ROA
Innovent Biologics, Inc. generates $2.18 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Innovent Biologics, Inc. produces operating cash flow of $2.84B, showing steady but balanced cash generation.
Free Cash Flow
Innovent Biologics, Inc. produces free cash flow of $2.34B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $1.36 in free cash annually.
FCF Yield
1801.HK converts 0.90% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
88.95
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-3.50
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.74
vs 25 benchmark
P/S Ratio
Price to sales ratio
10.61
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.15
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.62
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How 1801.HK Stacks Against Its Sector Peers
| Metric | 1801.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 88.95 | 28.31 | Worse (Expensive) |
| ROE | 4.82% | 699.00% | Weak |
| Net Margin | 6.30% | -130884.00% (disorted) | Weak |
| Debt/Equity | 0.15 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 2.62 | 2775.16 | Strong Liquidity |
| ROA | 2.18% | -14469.00% (disorted) | Weak |
1801.HK outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Innovent Biologics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
550.87%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
96.15%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
155.95%
Industry Style: Defensive, Growth, Innovation
High Growth